Literature DB >> 30550807

Increasing prevalence of the epidemic ribotype 106 in healthcare facility-associated and community-associated Clostridioides difficile infection.

Loreto Suárez-Bode1, Rubén Barrón1, José L Pérez1, Ana Mena2.   

Abstract

Clostridioides difficile is the leading cause of nosocomial diarrhea and antibiotics associated diarrhea, but it is also an increasingly common cause of community diarrhea. In recent years we have observed a progressive increase in the incidence of C. difficile infection (CDI) both at the hospital and community setting that could be explained by the dynamic epidemiology of C. difficile. The present study analyzes changes in the epidemiology of CDI for two years comparing healthcare facility-associated (HCFA) and community-associated (CA) CDI epidemiology, observed in a single laboratory setting. All new episodes of CDI diagnosed during the years 2015-2016 were included in the study and classified as HFCA-, CA- or indeterminate CDI. Isolates were characterized by ribotyping and antimicrobial susceptibility was also determined. A total of 272 primary episodes of different patients were included in the study and classified 55.5% as CA-, 32% as HO-HCFA, 6.25% as CO-HCFA and 6.25% as indeterminate CDI. Overall, ribotype 106 was the most prevalent and also, many patients who suffered recurrent episodes were associated with this ribotype (29%). In fact, ribotype 106 showed a significantly higher recurrence rate than other ribotypes (26% vs 11%, p = 0.03). Moreover, 46% of the moxifloxacin resistant isolates were ribotype 106. No significant differences of antimicrobial resistance were observed between HCFA- and CA-CDI isolates, although fluoroquinolone resistance rates were slightly higher in HCFA-CDI isolates (25% vs 18.5%), and fluoroquinolone resistant ribotypes 106 and 126 were more frequently associated to CA-CDI and ribotype 078 to HCFA-CDI. The increasing incidence of CDI in our health care area is partially explained by the growing prevalence of the epidemic ribotype 106, both in HFCA- and CA-CDI, probably favored by the higher resistance and recurrence rate associated to ribotype 106 isolates.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antimicrobial susceptibility; Clostridium difficile infection; Community-acquired CDI; Health-care facility-acquired CDI; Ribotype 106

Mesh:

Year:  2018        PMID: 30550807     DOI: 10.1016/j.anaerobe.2018.12.002

Source DB:  PubMed          Journal:  Anaerobe        ISSN: 1075-9964            Impact factor:   3.331


  3 in total

1.  Clostridioides difficile ribotype 106: A systematic review of the antimicrobial susceptibility, genetics, and clinical outcomes of this common worldwide strain.

Authors:  T J Carlson; D Blasingame; A J Gonzales-Luna; F Alnezary; K W Garey
Journal:  Anaerobe       Date:  2019-12-19       Impact factor: 3.331

2.  Characterization of Healthcare-Associated and Community-Associated Clostridioides difficile Infections among Adults, Canada, 2015-2019.

Authors:  Tim Du; Kelly B Choi; Anada Silva; George R Golding; Linda Pelude; Romeo Hizon; Ghada N Al-Rawahi; James Brooks; Blanda Chow; Jun C Collet; Jeannette L Comeau; Ian Davis; Gerald A Evans; Charles Frenette; Guanghong Han; Jennie Johnstone; Pamela Kibsey; Kevin C Katz; Joanne M Langley; Bonita E Lee; Yves Longtin; Dominik Mertz; Jessica Minion; Michelle Science; Jocelyn A Srigley; Paula Stagg; Kathryn N Suh; Nisha Thampi; Alice Wong; Susy S Hota
Journal:  Emerg Infect Dis       Date:  2022-04-26       Impact factor: 16.126

3.  Characterization of the virulence of three novel clade 2 Clostridioides (Clostridium) difficile strains and a two-year screening in animals and humans in Brazil.

Authors:  Amanda Nadia Diniz; Loren Nery Fontoura Moura; Diogo Soares Gonçalves Cruz; Carlos Augusto Oliveira Junior; Henrique César Pereira Figueiredo; João Luís Reis Cunha; Eduardo Garcia Vilela; Edward J Kuijper; Mark H Wilcox; Francisco Carlos Faria Lobato; Rodrigo Otávio Silveira Silva
Journal:  PLoS One       Date:  2022-08-26       Impact factor: 3.752

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.